These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33870733)

  • 1. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
    Myakala K; Jones BA; Wang XX; Levi M
    Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
    Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
    Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice.
    Esser N; Schmidt C; Barrow BM; Cronic L; Hackney DJ; Mongovin SM; Hogan MF; Templin AT; Castillo JJ; Hull RL; Zraika S
    Front Endocrinol (Lausanne); 2022; 13():888867. PubMed ID: 35733766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/valsartan alleviates sepsis-induced myocardial injury in rats via dual angiotensin receptor-neprilysin inhibition and modulation of inflammasome/caspase 1/IL1β pathway.
    Refaie MMM; El-Hussieny M; Bayoumi AMA; Abdelraheem WM; Abdel-Hakeem EA; Shehata S
    Eur J Pharmacol; 2024 Sep; 979():176834. PubMed ID: 39038638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
    Nishio H; Ishii A; Yamada H; Mori KP; Kato Y; Ohno S; Handa T; Sugioka S; Ishimura T; Ikushima A; Inoue Y; Minamino N; Mukoyama M; Yanagita M; Yokoi H
    Nephrol Dial Transplant; 2023 Oct; 38(11):2517-2527. PubMed ID: 37202215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
    Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
    J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
    Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
    Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
    Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
    Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF
    Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
    Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
    Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
    Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
    Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
    Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review.
    Zhang R; Sun X; Li Y; He W; Zhu H; Liu B; Zhang A
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484211058681. PubMed ID: 34994233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
    Burke RM; Lighthouse JK; Mickelsen DM; Small EM
    Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
    Nielsen EE; Feinberg JB; Bu FL; Hecht Olsen M; Raymond I; Steensgaard-Hansen F; Jakobsen JC
    Open Heart; 2020 Nov; 7(2):. PubMed ID: 33257469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strain-selective efficacy of sacubitril/valsartan on carotid fibrosis in response to injury in two inbred mouse strains.
    Korshunov VA; Quinn B; Faiyaz A; Ahmed R; Sowden MP; Doyley MM; Berk BC
    Br J Pharmacol; 2019 Aug; 176(15):2795-2807. PubMed ID: 31077344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
    Vilela-Martin JF
    Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/Valsartan inhibits M1 type macrophages polarization in acute myocarditis by targeting C-type natriuretic peptide.
    Liu C; Long Q; Yang H; Yang H; Tang Y; Liu B; Zhou Z; Yuan J
    Biomed Pharmacother; 2024 May; 174():116535. PubMed ID: 38581923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.